Tag Archives: carcinogenesis

Pesticides and Parkinson’s: UCLA Researchers Uncover Further Proof of a Link

Study suggests potential new target in fight against debilitating disease

For several years, neurologists at UCLA have been building a case that a link exists between pesticides and Parkinson’s disease. To date, paraquat, maneb and ziram — common chemicals sprayed in California’s Central Valley and elsewhere — have been tied to increases in the disease, not only among farmworkers but in individuals who simply lived or worked near fields and likely inhaled drifting particles.

Now, UCLA researchers have discovered a link between Parkinson’s and another pesticide, benomyl, whose toxicological effects still linger some 10 years after the chemical was banned by the U.S. Environmental Protection Agency. (more…)

Read More

Bacteria May Signal Pancreatic Cancer Risk

Pancreatic cancer is highly lethal and difficult to detect early. In a new study, researchers report that people who had high levels of antibodies for an infectious oral bacterium turned out to have double the risk for developing the cancer. High antibody levels for harmless oral bacteria, meanwhile, predicted a reduced pancreatic cancer risk.

PROVIDENCE, R.I. [Brown University] — A new study finds significant associations between antibodies for multiple oral bacteria and the risk of pancreatic cancer, adding support for the emerging idea that the ostensibly distant medical conditions are related.

The study of blood samples from more than 800 European adults, published in the journal Gut, found that high antibody levels for one of the more infectious periodontal bacterium strains of Porphyromonas gingivalis were associated with a two-fold risk for pancreatic cancer. Meanwhile, study subjects with high levels of antibodies for some kinds of harmless “commensal” oral bacteria were associated with a 45-percent lower risk of pancreatic cancer. (more…)

Read More

Solving The Mystery of An Old Drug That May Reduce Cancer Risk

In 2005, news first broke that researchers in Scotland found unexpectedly low rates of cancer among diabetics taking metformin, a drug commonly prescribed to patients with Type II diabetes. Many follow-up studies reported similar findings, some suggesting as much as a 50-per-cent reduction in risk. How could this anti-diabetic drug reduce the risk of developing cancer and what were the mechanisms involved?

In a paper published today in the journal Cancer Prevention Research, researchers from McGill University and the University of Montreal reported an unexpected finding: they learned that exposure to metformin reduces the cellular mutation rate and the accumulation of DNA damage. It is well known that such mutations are directly involved in carcinogenesis, but lowering cancer risk by inhibiting the mutation rate has never been shown to be feasible. (more…)

Read More